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ABSTRACT
Pulmonary Aspergillus infections are caused by the ubiquitous fungus mold when
spores found in compost, dust, and plant material are inhaled. Manifestation of the
disease is represented by a delicate balance between host and pathogen interactions,
making Aspergillus infection more commonly observed in immunocompromised
individuals. Chronic cavitary pulmonary aspergillosis (CCPA) is a subtype of pulmonary
Aspergillosis associated with a history of chronic or prior lung disease. Here, we present
the case of a non-immunocompromised 24-year-old male with a history of intermittent
asthma with chronic pulmonary symptoms and a finding of a lung mass on imaging. We
describe the diagnostic challenge and surgical treatment of CCPA in medically refractory disease. This case is unique because our patient is relatively young and otherwise
healthy, with no associated chronic lung disease.
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INTRODUCTION
The finding of a lung mass in a young person
harbors a diversely broad differential diagnosis.
When combined with the patient’s presenting
signs and symptoms, family history, tobacco use,
immunocompromise, and exposure to infectious
pathogens are important clues in making the
diagnosis. As the probability of malignancy rises
with age, malignant etiologies in those under
35 years of age are uncommon but should be
carefully investigated.1 Infectious granuloma is
the most common cause of benign lung masses,
while vascular abnormalities and benign tumors
represent other common etiologies.2
Mycobacteria, endemic fungi, and
Staphylococcus aureus are the most common
infectious agents.2 Careful questioning
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to elucidate the risk of exposure to these
pathogens is an important step in diagnosis.
Immunocompromised patients should also
be identified, as they are at increased risk for
fungal and mycobacterial infection. Pulmonary
Aspergillus infections should remain high on the
differential in immunocompromised patients and
those with a history of lung disease.
Aspergillus infection presents as a spectrum
of pulmonary diseases, including allergic,
invasive, and noninvasive aspergillosis. Allergic
bronchopulmonary aspergillosis (ABPA) is
almost exclusively found in immunocompetent
individuals with asthma and cystic fibrosis
(CF) and presents with central bronchiectasis
and recurrent CF or asthma exacerbations.3
Invasive aspergillosis is the most severe type of
pulmonary aspergillosis and commonly affects

mds.marshall.edu/mjm
© 2022 Marshall Journal of Medicine

Marshall Journal of Medicine
Volume 8 Issue 4

immunocompromised individuals, including
those severely neutropenic, hematopoietic
stem cell transplant recipients, organ transplant
recipients, patients on long-term corticosteroids,
and those with acquired and heredity
immunodeficiency.4 Chronic cavitary pulmonary
aspergillosis (CCPA), formerly referred to as
complex aspergilloma, is a subtype of chronic
noninvasive aspergillosis. In contrast to other
forms of pulmonary Aspergillosis infection, CCPA
is not associated with immunocompromise
but rather a prior or current lung disease
history.4 CCPA commonly presents with cough,
shortness of breath, sputum production, chest
pain, and hemoptysis.5 Patients may have
elevated inflammatory markers, and one-third
of patients have sputum culture with growth
of Aspergillus.5 CCPA is associated with high
morbidity and mortality due to life-threatening
massive hemoptysis.6
Here, we describe a 24-year-old male nonimmunocompromised patient with chronic
symptoms of hemoptysis, cough, and pleuritic
chest pain with radiographic evidence of
worsening cystic lung masses and culture
positive for Aspergillus, diagnosed with CCPA.
CASE
Our patient is a 24-year-old male who initially
presented to his primary care physician
(PCP) in October 2019 with an intermittent
non-productive cough which progressed
to hemoptysis with white/green sputum
and intermittent pleuritic chest pain over 4
months. He denied fevers, chills, weight loss,
and lymphadenopathy. Our patient has a past
medical history of intermittent asthma, for
which he was prescribed a combination longacting beta agonist inhaled corticosteroid
(LABA-ICS) inhaler, which he seldomly used.
He has no history of tuberculosis or human
immunodeficiency virus (HIV). He has used 1 can
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of smokeless tobacco daily for the past 10 years
and has never smoked or used illicit drugs. He
has worked as a welder at a coal mine since 2017
and worked on a farm prior to this. Workup of his
symptoms by his PCP included chest computed
tomography (CT), which revealed a right upper
lobe (RUL) lung mass suspicious for malignancy
(Figure 1, C). Urine histoplasma antigen, HIV, and
Interferon Gamma Release Assay (IGRA) were
negative.
He was referred to thoracic surgery in January
2020 due to failed biopsy attempts at an outside
facility. His symptoms remained stable, and he
was started on a 2-week course of doxycycline.
Chest CT showed the RUL mass contained
multiple cysts with low attenuation, with the
largest cystic component increasing in size from
4.3 cm to 5.3 cm since the previous study. The
patient underwent navigator bronchoscopy
with brushings in February 2020, and cytology
revealed normal-appearing bronchial cells with
no evidence of malignancy. Fungal, bacterial,
and acid-fast bacilli (AFB) cultures were negative.
He was referred to infectious disease due to
no improvement of his symptoms. Infectious
disease and thoracic surgery recommended CTguided biopsy.
In May 2020, the patient underwent CT guided
biopsy with core biopsies sent for AFB and
fungal culture (Figure 1, A). On follow-up with
thoracic surgery, he complained of increasing
chest pain and hemoptysis. Histology at this
time was negative for malignancy, while cultures
grew Aspergillus with further species unable
to be elucidated. At this point, the patient was
lost to follow-up from thoracic surgery and the
infectious disease clinic.
In January 2021, the patient returned to the
thoracic surgery clinic. The patient reported that
he was started on itraconazole by a provider
at an outside facility and that his symptoms
had remained stable. He was again referred
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to infectious disease, who saw him in March
2021 when they discontinued itraconazole and
started voriconazole. The patient complained of
intermittent chest pain at this time, although his
cough had improved. The patient continued to
have good follow-up with infectious disease and
tolerated voriconazole well.
In November 2021, he was seen in the ER at
an outside facility for chest pain. His chest
CT showed a chronic multifocal collection
of pulmonary nodular lesions in the RUL,
unchanged from the prior CT 11 months ago.
He was seen again by thoracic surgery, where

surgical management of residual disease was
planned. In January 2022, he underwent right
upper lobe wedge dissection with resection of
residual post-disease. Interventional radiology
was consulted for the CT-guided placement
of a fiducial coil at the posterior margin of
the RUL disease process to ensure complete
removal. A 4.8 x 1.7 x 1.4 cm wedge resection
with multiple cystic components was removed
(Figure 2). The patient tolerated the procedure
well. Fungal, bacterial, and AFB cultures were
negative. Chronic granulomatous inflammation
was seen on histology (Figure 2, C). The patient
returned to thoracic surgery and the infectious

FIGURE 1. Pre- and postoperative CT images of CCPD. Non-contrast CT images in
coronal and sagittal planes viewed through lung window. Postoperative images
completed 4 months post wedge resection. A: CT guided biopsy of cystic right anterior lobe mass completed May 2020. B: Postoperative view of upper lobe reveals
no evidence of mass or cystic components. C: Sagittal view of right anterior upper
lobe reveals multiple cystic-appearing components with the largest seen against
the mediastinum. Completed December 2019. D: Postoperative sagittal view
reveals no evidence of lung mass.
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FIGURE 2. Intraoperative specimen. Residual pulmonary aspergillosis was resected
by right upper lobe wedge dissection. A: Gross specimen shows a 4.8 x 1.7 x 1.4
cm wedge of the right upper lobe. Multiple cystic-appearing components contained in the wedge. Staple line can be seen. B: Multiple cystic pockets expressed
opaque material when incised. C: Right upper lobe wedge resection showing lung
parenchyma with focal chronic inflammation and granulomatous inflammation.
No fungal organisms identified.

disease clinic for follow-up and denied chest
pain, cough, hemoptysis, and dyspnea. A
6-month course of voriconazole was started
postoperatively. CT chest 4-months post-op
showed no residual disease (Figure 1, B & D).
DISCUSSION
Diagnosis and control of disease in CCPA
is a challenging task. Diagnosis of CCPA
requires symptoms and radiologic features
to be present for at least 3 months, no
or minimal immunosuppression, and
microbiologic (Aspergillus growth in culture
or sputum polymerase chain reaction (PCR))
or immunologic (elevated Aspergillus IgG
antibody) evidence of Aspergillus infection.4
Various radiographic findings are found on CT
imaging, including cavitations in the upper
lung lobes that may contain fungal balls,
bronchiectasis, pleural thickening, and effusions,
making early CCPA diagnosis challenging.12
Our patient lacks traditional risk factors
for Aspergillus infection, including prior
tuberculosis infection, malignancy, AIDS, and
immunocompromised state. Our patient has
a 5-year history of working in a coal mine,
prior work on a farm, a 10-year history of
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smokeless tobacco use, and a history of asthma
with non-compliant combination LABA-ICS
inhaler use. “Farmer’s lung” has classically been
described as inoculation with A. fumigatus in
non-immunocompromised hosts in highlycolonized environments such as farms.13 A small
number of reports have described associations
between Aspergillus infection and work in coal
mines, including the increased presence of A.
fumigatus in the sputum of coal miners with coal
workers’ pneumoconiosis.14 This combination
of subtle immunodeficiency with tobacco
use and asthma, combined with our patient’s
history of work in potentially highly-colonized
environments, may have led to the development
of CCPA.
CCPA is often treated pharmacologically, while
surgical intervention is typically reserved for
patients with persistent symptomatic local
disease refractory to medical management
and those with hemoptysis unresponsive to
treatment. Patients with symptomatic CCPA
require a minimum of 6 months of treatment
with oral itraconazole or voriconazole.4
Our patient with CCPA had symptomatic
disease refractory to approximately 1 year of
itraconazole and 6 months of voriconazole
treatment. Benign-appearing surrounding
lung parenchyma and normal pulmonary
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function testing indicated that he was a
candidate for surgical resection. Symptomatic
patients with a single aspergilloma or CCPA
with localized disease may undergo surgical
resection for disease control. Better outcomes
have been described in the resection of
single aspergillomas when compared to
CCPA, including decreased recurrence rate
and reduced post-op complications such
as bleeding, air leak, and pneumothorax.15
In localized disease, wedge resection is the
recommended surgical approach to preserve
lung tissue.16 Local resection is associated with
better outcomes, including reduced length
of postoperative antibiotics.6,16 Our patient
tolerated local wedge resection well, with no
complications postoperatively, and has been
compliant with 5 months of post-operative
voriconazole to date.
CONCLUSION
Pulmonary aspergillosis is a rare fungal
infection that should always be included in the
differential diagnosis of patients with chronic
cough, hemoptysis, and pleuritic chest pain with
radiographic findings of a lung mass. This case is
unusual because our patient is relatively young
and otherwise healthy, with no associated
chronic lung disease. CCPA unresponsive to oral
first-line antifungal therapy should consider
surgical resection of disease in the setting of
good overall pulmonary function and localized
disease with a 6-month course of oral antifungal
postoperatively.
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